Literature DB >> 18040092

Are somatoform disorders changing with time? The case of neurasthenia in China.

Sing Lee1, Arthur Kleinman.   

Abstract

OBJECTIVE: To examine how sociocultural factors shape the professional classification and transformation of neurasthenia (shenjing shuairuo in the Chinese language) in China.
METHODS: We review the relevant literature as well as cite our own research experience on the topic.
RESULTS: We identify three main periods of transformation, namely, the prereform period (before 1980) in which neurasthenia encompassed a wide range of anxiety and mood disorders; the reform period (1980s-1995) when the Diagnostic and Statistical Manual of Mental Disorders-III (DSM-III) and Kleinman's study in Hunan steadily shaped the Chinese conceptualization of nonpsychotic mental disorders; and the postreform period (after 1995) when neurasthenia has become a rarely used category of subsyndromal depression among Chinese psychiatrists.
CONCLUSIONS: The dramatic transformation of neurasthenia in China speaks to the global power of the DSM system of classification, on the one hand, and the latter's failure to engage cultures in the local system of psychiatric practice, on the other. The Chinese story of neurasthenia and the social context in which the disease category is contested, marginalized, and reconstituted as the popular Western disease of depression among Chinese psychiatrists attest to the socially constructed nature of psychiatric classification. The public health implications of this transformation remain unclear.

Entities:  

Mesh:

Year:  2007        PMID: 18040092     DOI: 10.1097/PSY.0b013e31815b0092

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  13 in total

Review 1.  Measuring the impact of programs that challenge the public stigma of mental illness.

Authors:  Patrick W Corrigan; Jenessa R Shapiro
Journal:  Clin Psychol Rev       Date:  2010-06-30

Review 2.  Psychosocial determinants of irritable bowel syndrome.

Authors:  Teodora Surdea-Blaga; Adriana Băban; Dan L Dumitrascu
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

3.  Depression as a culture-bound syndrome: implications for primary care.

Authors:  Christopher Dowrick
Journal:  Br J Gen Pract       Date:  2013-05       Impact factor: 5.386

4.  A Moderated Mediation Analysis on the Association Between Perceived Discrimination and Physical Symptoms Among Immigrant Women from Mainland China into Hong Kong: Evidence from the FAMILY Cohort.

Authors:  Nancy Xiaonan Yu; Michael Y Ni; Sunita M Stewart
Journal:  J Immigr Minor Health       Date:  2021-06

5.  Prevalence of neurasthenia, comorbidity, and association with impairment among a nationally representative sample of US adults.

Authors:  Kristine M Molina; Chih-Nan Chen; Margarita Alegría; Huijun Li
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-02-17       Impact factor: 4.328

6.  Prevalence of physical symptoms and their association with race/ethnicity and acculturation in the United States.

Authors:  Amy M Bauer; Chih-Nan Chen; Margarita Alegría
Journal:  Gen Hosp Psychiatry       Date:  2012-03-27       Impact factor: 3.238

7.  The domains of psychiatric practice: from centre to periphery.

Authors:  Dominique Pareja Béhague
Journal:  Cult Med Psychiatry       Date:  2008-06

8.  Recognition and treatment of depression: a comparison of Australian and Chinese medical students.

Authors:  Ye Rong; Georgina M Luscombe; Tracey A Davenport; Yueqin Huang; Nick Glozier; Ian B Hickie
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-11-20       Impact factor: 4.328

9.  Culture and Context in Mental Health Diagnosing: Scrutinizing the DSM-5 Revision.

Authors:  Anna Bredström
Journal:  J Med Humanit       Date:  2019-09

10.  The effects of the gender-culture interaction on self-reports of depressive symptoms: cross-cultural study among Egyptians and Canadians.

Authors:  Vivian Huang; Shadi Beshai; Mabel Yu
Journal:  PeerJ       Date:  2016-12-07       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.